Description
BSE notifies trading members that Biogen Pharmachem Industries Limited has fixed May 15, 2026 as the record date for a bonus issue of 1 equity share for every 6 shares held.
Summary
BSE has notified trading members that Biogen Pharmachem Industries Limited (Scrip Code: 531752) has fixed May 15, 2026 as the record date for a bonus issue. The company will issue 1 (one) bonus equity share of Re. 1/- each for every 6 (six) equity shares of Re. 1/- each held. Trading in the equity shares will be on an ex-bonus basis effective May 15, 2026.
Key Points
- Bonus ratio: 1:6 — one bonus equity share for every six shares held
- Face value: Re. 1/- per share
- Record date: May 15, 2026
- Ex-bonus date: May 15, 2026 (Settlement No. DR-631/2026-2027)
- Allotment date: 15,04,33,833 equity shares to be allotted on May 18, 2026
- Notice issued by Marian Dsouza, Assistant Vice President – Listing Compliance and Operations
Regulatory Changes
No new regulatory changes. This is a standard corporate action notification pursuant to BSE listing requirements.
Compliance Requirements
- Trading members must treat transactions in Biogen Pharmachem Industries Limited equity shares as ex-bonus from May 15, 2026 onwards.
- Members should update their systems to reflect the new share capital post-allotment on May 18, 2026.
Important Dates
| Event | Date |
|---|---|
| Notice Date | May 13, 2026 |
| Record Date | May 15, 2026 |
| Ex-Bonus Effective Date | May 15, 2026 |
| Bonus Share Allotment Date | May 18, 2026 |
Impact Assessment
The bonus issue increases the share count of Biogen Pharmachem Industries Limited by approximately 1/6th of its existing capital, with 15,04,33,833 new equity shares being allotted. The share price is expected to adjust proportionally on the ex-bonus date (May 15, 2026). Existing shareholders as of the record date will receive one additional share for every six held at no cost, improving liquidity and affordability of the stock. No material impact on broader market operations.
Impact Justification
Routine corporate action (bonus issue) affecting existing shareholders of Biogen Pharmachem Industries Limited; no systemic market impact but directly relevant to holders of scrip 531752.